Skip to content
Open access

ASOCompass: Context- and Chemistry-Aware Activity Prediction for Transferable Antisense Oligonucleotide Screening

Aug 2026 · bioRxiv · 0 citations · 38 references
Biology

TL;DR

ASOCompass, a context-and chemistry-aware framework for ASO activity prediction and candidate ranking, is introduced and the potential of jointly modeling sequence, chemistry, and experimental-biological context for transferable ASO screening is demonstrated.

Abstract

Antisense oligonucleotide (ASO) activity is jointly influenced by nucleotide sequence, chemical modification, target-RNA context, dose, delivery protocol, and cellular environment. Most existing computational screening methods model only a subset of these factors, limiting their ability to predict experimentally measured activity across heterogeneous screening conditions and previously unseen biological contexts. We introduce ASOCompass, a context-and chemistry-aware framework for ASO activity prediction and candidate ranking. ASOCompass integrates contextualized ASO and target-RNA sequence representations with position-specific molecular representations of chemical modifications. It further incorporates dose and delivery information together with prototype-adapted transcriptomic representations of target genes and cell lines. To encourage chemically and biophysically informative representations, the model is jointly trained on auxiliary molecular-property and sequence-derived thermodynamic prediction tasks. We evaluate ASOCompass on ASO Atlas, a large patent-derived dataset of RNase H-mediated gapmer ASOs, under held-out drug, target-gene, cell line, and joint gene–cell line settings. ASOCompass achieves an overall Spearman correlation of 0.5970, improving over the strongest ASO-specific baseline by 0.0421, and consistently performs best across all four distribution shifts. When adapted to unseen SOD1 and KLKB1 targets, ASOCompass also provides more accurate candidate ranking across different annotation budgets, reaching correlations of 0.830 and 0.696 with 1,024 target-specific labels. Additional analyses suggest that molecular-property supervision improves modification-specific ranking, while the auxiliary thermodynamic task produces representations more closely aligned with measured inhibition. These results demonstrate the potential of jointly modeling sequence, chemistry, and experimental-biological context for transferable ASO screening.

Read PDF

Similar papers

Open access Sep 2026

ASOFormer: a Transformer-based model for predicting antisense oligonucleotide efficacy to support therapeutic candidate prioritization

Antisense oligonucleotides (ASOs) represent a promising therapeutic modality for RNA-based disease mechanisms, but identifying high-efficacy candidates from large sequence spaces remains a major bottleneck in drug development. Here, we present ASOFormer, a novel Transformer-based neural network that predicts the inhibi...

N. Dove, Yu-Hao Min, Özkan Iş et al. · 0 citations
Open access Sep 2026

LLM-guided prediction of riboswitch-ligand binding affinity under data-limited conditions.

Riboswitches are RNA regulatory elements that sense small molecules and regulate gene expression through ligand-induced conformational changes in an aptamer domain. They enable synthetic biology applications such as biosensing and gene circuit design. Accurate prediction of riboswitch-ligand binding affinity, quantifie...

Sunggi An, Sofia Mun, Yousung Jung et al. · 0 citations
Open access Sep 2026

AET5: A transcriptome-guided molecular generation framework with contrastive self-supervised learning

Gene expression profiles capture system-level drug responses and offer a promising basis for de novo molecular generation. However, their application is limited by data sparsity and experimental noise, which hinder the reliable mapping between disease-associated transcriptomic perturbations and chemically valid therape...

Zhi-Kang Yuan, Xin Zhang, Gao-Ming Lin et al. · 0 citations
Open access Sep 2026

HARIBOSS++: An Integrated Platform for RNA-Targeted Drug Design

Targeting RNA with small molecules is increasingly viewed as a pivotal strategy for future therapeutics. A major limitation in studying RNA-small molecule (RNA-SM) interactions is the lack of available experimental structures. HARIBOSS established a milestone as a curated database of RNA-SM complexes derived from the P...

Matteo Marengo, Elodie Chapeaublanc, Hervé Ménager et al. · 0 citations
Open access Sep 2026

DLRNA-BERTa: a transformer approach for predicting molecule-RNA binding affinities

Abstract Therapies targeting RNA are rapidly expanding, with 24 FDA-approved RNA therapeutics and over 130 currently in clinical trials, highlighting RNA’s growing role in drug discovery. In this context, transformer-based language models provide a scalable and cost-effective approach to accelerate RNA-targeted drug di...

Pasquale Lobascio, Khalid Saeed, Asifullah Khan et al. · 0 citations
#artificial intelligence Preprint Sep 2026

One Sequence, Many Decodings: CAGenMol-2 Recasts Drug Design as Masked Molecular Inference

Drug design couples property evaluation, conditional generation, structure-based design, and local optimization, yet machine learning systems typically address these capabilities with separate task-specific models. We introduce CAGenMol-2, a masked diffusion molecular language model that represents molecules, continuou...

Yan-Ting Li, En-Yang Dai, Lei Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.